{
    "nct_id": "NCT05215574",
    "official_title": "A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.\n* Adequate bone marrow, kidney and liver function\n* Performance status of 0 or 1.\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment targeting ILT3.\n* Prior treatment targeting LAIR1.",
    "miscellaneous_criteria": ""
}